IP Library Granted Patent US 9,051,267
Granted Patent B2
US 9,051,267 · App. 14/043,554 · Granted Jun 9, 2015

Estrogen receptor ligands and methods of use thereof

Inventors: James T. Dalton (Lakeland, TN); Mitchell S. Steiner (Germantown, TN); Jeetendra Eswaraka (Carlsbad, CA)
Assignee: GTX, INC.
C07D211/06A61K31/445C07D221/12C07D295/155A61K31/137A61K31/167C07C215/82C07C233/75C07C235/56
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,051,267
App. No.
14/043,554
Granted
Jun 9, 2015
Kind
B2
Abstract

The present invention relates to methods of treating androgen deprivation therapy (ADT) induced hot flashes and severe hot flashes in a subject.

Claims (10)

1. A compound, or a pharmaceutically acceptable salt thereof, wherein said compound is:

2. The compound of claim 1 , wherein said pharmaceutically acceptable salt is a bisulfate, borate, bromide, chloride, hemisulfate, hydrobromate, hydrochlorate, hydroxyethylsulfonate, iodate, iodide, isothionate, nitrate, persulfate, phosphate, sulfate, sulfamate, sulfanilate, sulfonic acid, sulfonate or thiocyanate, acetate, oxalate, tartrate, mandelate, citrate, sodium, potassium, ammonium, calcium, trimethylamine, or procaine.

3. The compound of claim 1 , wherein said pharmaceutically acceptable salt is a hydrochloride salt.

4. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a suitable carrier or diluent.

5. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is in a liquid form for intravenous, intraarterial or intramuscular injection to a subject.

6. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is for subcutaneous implantation in a subject.

7. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is in a liquid or solid form for oral administration to a subject.

8. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is for topical application to the skin surface of a subject.

9. The pharmaceutical composition of claim 4 , wherein the pharmaceutical composition is a tablet, a capsule, a solution, a suspension, an emulsion, an elixir, a gel, a suppository or a parenteral formulation.

10. The pharmaceutical composition of claim 4 , wherein said pharmaceutical composition is a patch.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 9, 2014
From: DALTON, JAMES T.; STEINER, MITCHELL S.; ESWARAKA, JEETENDRA
To: GTX, INC.
Reel/Frame 032633/0975 →
Continuity (10)
Continuation 12710693 · Feb 23, 2010
Continuation In Part 11785251 · Apr 16, 2007
Continuation In Part 11604884 · Nov 28, 2006
Continuation In Part 14043554
Continuation In Part 13362242 · Jan 31, 2012
Provisional Application 60739898 · Nov 28, 2005
Provisional Application 61261669 · Nov 16, 2009
Provisional Application 61168983 · Apr 14, 2009
Provisional Application 61154707 · Feb 23, 2009
Related Publication 20140171468A1 · Jun 19, 2014